Please assess the completion status of the following clinical trial:

Trial Title: Improve Management of Heart Failure With Procalcitonin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who present to the emergency department (ED) with leading symptom dyspnea~2. Suspected or known heart failure~3. midregional pro atrial natriuretic peptide (MR-proANP)\>300 pmol/L, brain natriuretic peptid (BNP) \>350 ng/ml or N-terminal of the prohormone brain natriuretic peptide (NT-proBNP)\>1800 ng/l~4. Patient has given written Informed Consent within study timelines to allow antibiotic therapy within 8 hours~5. Adult patients (i.e. \>18 years of age)~6. Hospitalization for at least 1 overnight stay planned~Exclusion Criteria:~1. Patient participates in any other interventional clinical trial~2. Trauma related shortness of breath~3. Patient diagnosed with lung or thyroid cancer~4. Known terminal disease with life expectancy of less than 6 months, e.g. advanced metastasized cancer disease~5. Organ transplant requiring immunosuppression~6. Abdominal, vascular or thorax surgery within the last 30 days~7. End stage/advanced heart failure - defined by planned heart transplantation, or cardiogenic shock~8. Female patients who have given birth within 3 months before study enrolment~9. Current use of antibiotics or requirement of immediate antibiotic therapy before randomization and measurement of Procalcitonin~10. End stage renal failure requiring dialysis~11. Patient is not willing, or it is not possible or advisable for the patient, to follow the study schedule, including antibiotic therapy and 90 days follow up~12. Patient has already participated in the clinical trial previously~13. Pregnant or lactating women~14. Patients who are institutionalized by official or judicial order~15. Dependants of the sponsor, the contract research organization (CRO), the study site or the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCT-guided (Type: EXPERIMENTAL): Blood samples are taken on day 0 and day 1 of the study. Procalcitonin (PCT) is measured and used support the decision on antibiotic therapy.~PCT levels above 0.2 ng/ml: antibiotic therapy is recommended PCT levels equal/below 0.2 ng/ml: antibiotic therapy is not recommended
- Standard of Care (Type: NO_INTERVENTION): Blood samples are taken on day 0 and day 1 and stored for later analysis. The investigator treats the patients according to standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).